CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL Economic and Quality-of-Life Outcomes of Natriuretic Peptide–Guided Therapy for Heart Failure Phenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial Frequency, predictors, and prognosis of ejection fraction improvement in heart failure: an echocardiogram-based registry study Circulating sST2 and catestatin levels in patients with acute worsening of heart failure: a report from the CATSTAT-HF study Association of Prior Left Ventricular Ejection Fraction With Clinical Outcomes in Patients With Heart Failure With Midrange Ejection Fraction

Original Research2018 Jun 5;71(22):2497-2506.

JOURNAL:J Am Coll Cardiol. Article Link

SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL

Cavender MA, Norhammar A, CVD-REAL Investigators and Study Group. Keywords: CVD-REAL; cardiovascular disease; heart failure; sodium-glucose co-transporter-2 inhibitors

FULL TEXT PDF